Range Impact (RNGE) 10-K 29 Jun 20 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2020	Jun. 26, 2020	Sep. 30, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	Vitality Biopharma, Inc.
Entity Central Index Key	0001438943
Document Type	10-K
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 4,091,568
Entity Common Stock, Shares Outstanding		50,840,147
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Current Assets
Cash and cash equivalents	$ 2,392,225	$ 5,982,741
Prepaid expenses and other current assets	15,666	3,300
Current assets, discontinued operations		66,607
Total current assets	2,407,891	6,052,648
Deposits	35,752	22,662
Operating lease right-of-use asset	123,606
Total Assets	2,567,249	6,075,310
Current Liabilities
Accounts payable and accrued liabilities	862,528	640,965
Advance	296,653	296,653
Operating lease liability, short-term	125,679
Accounts payable - related party		5,200
Derivative liability		35,710
Current liabilities, discontinued operations		75,706
Total liabilities	1,284,860	1,054,234
Commitments and contingencies
Stockholders' Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 50,840,147 and 52,290,147 shares issued and outstanding, respectively	50,640	52,090
Additional paid-in-capital	47,778,607	47,150,489
Accumulated deficit	(46,546,858)	(42,181,503)
Total stockholders' equity	1,282,389	5,021,076
Total Liabilities and Stockholders' Equity	$ 2,567,249	$ 6,075,310

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Mar. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	50,840,147	52,290,147
Common stock, shares outstanding	50,840,147	52,290,147

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues
Operating Expenses:
General and administrative	2,680,217	2,792,703
Research and development	1,009,894	1,742,919
Rent- related party	2,600	31,200
Total operating expenses	3,692,711	4,566,822
Loss from operations	(3,692,711)	(4,566,822)
Other income
Change in fair value of derivative liability	35,710	117,332
Interest income	1,248
Other income	23,524
Total other income	60,482	117,332
Loss from continuing operations	(3,632,229)	(4,449,490)
Loss from discontinued operations	(733,126)	(8,672,077)
Net loss	(4,365,355)	(13,121,567)
Deemed dividend on issuance of shares		(7,015,000)
Net loss attributable to common stockholders	$ (4,365,355)	$ (20,136,567)
Net loss per share from continuing operations - basic and diluted	$ (0.07)	$ (0.13)
Net loss per share from discontinued operations - basic and diluted	(0.01)	(0.48)
Net loss per share - basic and diluted	$ (0.08)	$ (0.61)
Weighted average number of common shares outstanding - basic and diluted	51,541,377	33,001,323

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Mar. 31, 2018	$ 24,075	$ 22,343,135	$ (22,044,936)	$ 322,274
Balance, shares at Mar. 31, 2018	24,275,147
Shares and warrants issued for cash, net	$ 6,000	8,844,000		8,850,000
Shares and warrants issued for cash, net, shares	6,000,000
Shares issued for acquisition (net of 1,000,000 shares cancelled)	$ 5,000	7,495,000		7,500,000
Shares issued for acquisition (net of 1,000,000 shares cancelled), shares	5,000,000
Deemed dividend on issuance of shares	$ 16,750	6,998,250	(7,015,000)
Deemed dividend on issuance of shares, shares	16,750,000
Fair value of common stock issued for services	$ 265	348,186		348,451
Fair value of common stock issued for services, shares	265,000
Common stock issued to employees with vesting terms		356,270		356,270
Fair value of vested stock options		765,648		765,648
Net Loss			(13,121,567)	(13,121,567)
Balance at Mar. 31, 2019	$ 52,090	47,150,489	(42,181,503)	5,021,076
Balance, shares at Mar. 31, 2019	52,290,147
Fair value of vested stock options		626,668		626,668
Cancellation of shares	$ (1,450)	1,450
Cancellation of shares, shares	(1,450,000)
Net Loss			(4,365,355)	(4,365,355)
Balance at Mar. 31, 2020	$ 50,640	$ 47,778,607	$ (46,546,858)	$ 1,282,389
Balance, shares at Mar. 31, 2020	50,840,147

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Mar. 31, 2019shares
Statement of Stockholders' Equity [Abstract]
Number of shares cancelled during period	1,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (4,365,355)	$ (13,121,567)
Less: Loss from discontinued operations	733,126	8,672,077
Loss from continuing operations	(3,632,229)	(4,449,490)
Adjustments to reconcile loss from continuing operations to net cash used in operating activities:
Fair value of vested stock options	626,668	765,648
Fair value of vested restricted common stock		348,451
Fair value of common stock issued for services		356,270
Operating lease expense	129,781
Change in fair value of derivative liability	(35,710)	(117,332)
Changes in operating assets and liabilities:
Prepaid expense and other current assets	(12,366)	(14,643)
Prepaid expense - related party		2,600
Deposits	(13,090)	(2,028)
Accounts payable and accrued liabilities	221,563	429,817
Accounts payable - related party	(5,200)	5,200
Advance		296,653
Operating lease liability	(127,708)
Net cash used in operating activities - continuing operations	(2,848,291)	(2,378,854)
Net cash used in operating activities - discontinued operations	(742,225)	(1,286,240)
Net cash used in operating activities	(3,590,516)	(3,665,094)
Cash flows from investing activities:
Cash provided by discontinued operations		141,545
Net cash provided by investing activities		141,545
Cash provided by financing activities:
Proceeds from sale of common stock and warrants, net		8,850,000
Net cash provided by financing activities		8,850,000
Net increase (decrease) in cash and cash equivalents	(3,590,516)	5,326,451
Cash and cash equivalents - Beginning of Period	5,982,741	656,290
Cash and cash equivalents - End of Period	2,392,225	5,982,741
Supplemental disclosure of cash flow information:
Cash paid during the period for: Interest
Cash paid during the period for: Income taxes
Supplemental non-cash investing and financing activities:
Initial recognition of operating lease right-of-use assets and operating lease obligations upon adoption of new lease accounting standard	253,387
Cancellation of shares	1,450
Fair value of common stock of $7,500,000 issued in acquisition allocated to:
Current assets		168,046
Fixed assets		12,269
Costs in excess of net assets acquired		7,550,000
Current liabilities assumed		(230,315)
Fair value of common stock issued as dividend, net of warrants cancelled		$ 7,015,000

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical)	12 Months Ended
	Mar. 31, 2019USD ($)
Statement of Cash Flows [Abstract]
Fair value of common stock issued in acquisition	$ 7,500,000

Business Operations and Summary

Business Operations and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Operations and Summary of Significant Accounting Policies	1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. In 2015, the Company developed a new class of cannabinoids known as cannabosides, which were discovered through application of the Company’s proprietary enzymatic bioprocessing technologies. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides. Currently, we do not have any commercial products and have not yet generated any revenues from our cannabinoid prodrug pharmaceuticals. Liquidity We are currently engaged in the development of cannabinoid prodrug pharmaceuticals, we do not have any commercial products, and have not yet generated significant revenues from sales of products or services. As reflected in the accompanying financial statements, during the year ended March 31, 2020, the Company incurred a net loss of $4,365,355 and used $3,590,516 of cash in our operating activities. As of March 31, 2020, we had $2,392,225 of cash on hand, stockholders’ equity of $1,282,389 and working capital of $1,123,031. Our total expenditures for the fiscal year ending March 31, 2021, are expected to be approximately $1,600,000, which is comprised of research and development and general operating expenses. We believe that we have sufficient capital to fund our anticipated operating expenses for at least one year from the date that the financial statements are issued. While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations, we may require additional financing to fund our planned future operations. Further, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company. COVID-19 Outbreak The global outbreak of COVID-19 has led to significant disruptions in the global economy, including the curtailment of activities by businesses and consumers in much of the world as governments and others seek to limit the spread of the disease. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration and severity of the outbreak, the length of restrictions and business closures imposed by domestic and foreign governments, the impact on capital and financial markets, all of which are highly uncertain and cannot be predicted. While it is not possible at this time to estimate the full impact that COVID-19 will have on our business, restrictions resulting from COVID-19 on general economic conditions could, among other things, impair our ability to raise capital when needed. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently. Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Vitality Healthtech, Inc. and have been prepared in accordance with accounting principles generally accepted in the United States of America. Intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year end is March 31. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, estimates inherent in recording purchase price allocation, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. Business Combinations The Company accounts for its business combinations using the purchase method of accounting where the cost is allocated to the underlying net tangible and intangible assets acquired, based on their respective fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Identifiable assets acquired, liabilities assumed and any noncontrolling interest in the acquiree are recognized and measured as of the acquisition date at fair value. Additionally, contingent consideration, if any, is recorded at fair value on the acquisition date and classified as a liability. Goodwill is recognized to the extent by which the aggregate of the acquisition-date fair value of the consideration transferred and any noncontrolling interest in the acquiree exceeds the recognized basis of the identifiable assets acquired, net of assumed liabilities. Determining the fair value of assets acquired, liabilities assumed and noncontrolling interests requires management’s judgment and often involves the use of significant estimates and assumptions. Goodwill and Intangible Assets The Company follows Accounting Standards Codification (ASC) 350 in accounting for intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Under the guidance of ASC 350, goodwill is not amortized, rather it is tested for impairment annually, and will be tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss generally would be recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit and would be measured as the excess carrying value of goodwill over the derived fair value of goodwill. For the year ended March 31, 2019, the Company recorded impairment of goodwill and intangible assets of $7,550,000 (See Note 2). For the year ended March 31, 2020, the Company did not record any impairment of goodwill and intangible assets. Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. As of March 31, 2020 and March 31, 2019, the Company’s balance sheet includes Level 2 liabilities comprised of the fair value of embedded derivative liabilities of $0 and $35,710, respectively (see Note 5). The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative during the years ended March 31, 2020 and 2019: Year ended March 31, 2020 Year ended March 31, 2019 Fair value at beginning of period $ 35,710 $ 153,042 Net change in the fair value of derivative liabilities (35,710 ) (117,332 ) Fair value at end of period $ - $ 35,710 Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the March 31, 2020, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date. Leases Prior to April 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases Leases Stock-Based Compensation The Company issues stock options and warrants, shares of common stock, and shares of restricted common stock as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with ASC 718, Compensation – Stock Compensation In prior periods through March 31, 2019, the Company accounted for share-based payments to non-employees in accordance with ASC 505-50, Equity - Based Payments to Non-Employees On April 1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-07 which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions is measured by estimating the fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions. The adoption of the standard did not have a material impact on our financial statements. Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: March 31, 2020 2019 Options 6,546,710 3,456,710 Warrants 1,135,003 1,135,003 Total 7,681,713 4,591,713 Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Accordingly, patent costs are expensed as incurred. Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred. Segments The Company operates in one segment for the development of pharmaceuticals products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements. Reclassifications Certain amounts related to revenue and expenses of discontinued operations for the year ended March 31, 2019, and assets and liabilities attributable to discontinued operations at March 31, 2019, have been reclassified to conform to classifications used in the current year as a result of the discontinued operations presentation. The reclassifications had no effect on previously reported results of consolidated operations or retained earnings (see Note 2). Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	2. DISCONTINUED OPERATIONS In October 2018, the Company acquired Summit Healthtech, Inc., now known as Vitality Healthtech, Inc. and its subsidiary The Control Center, Inc. (collectively, “Summit Healthtech”). Summit Healthtech was formed to establish specialty healthcare clinics focused on treating patients suffering from addiction and dependency issues. In May 2019, the Company decided to close Summit Healthtech due to poor financial and operating performance. Summit Healthtech ceased all operations and closed on June 14, 2019. The Company initially issued 6,000,000 shares of the Company’s common stock valued at $9,000,000 in exchange for all of the outstanding common stock of Summit Healthtech. The shares were valued at $1.50 per share based on a contemporaneous private placement offering price. The Company accounted for the acquisition of Summit Healthtech as a business combination in accordance with ASC 805, Business Combinations In addition to the clinical operations of Summit Healthtech, the Company was engaged in the business of selling research diagnostic testing kits (collectively referred to as the “Company’s clinical and test kit operations”). In May 2019, the Company decided to close the Company’s clinical and test kit operations. The Company’s clinical and test kit operations meet the discontinued operations criteria and are reported as such in all periods presented on the accompanying consolidated financial statements. During the year ended March 31, 2020, costs to close the Company’s clinical and test kit operations, primarily made up of severance and related benefits, totaled approximately $165,000, and are included in loss from discontinued operations. Included in the 6,000,000 shares of common stock issued for the acquisition of Summit Healthtech were 1,450,000 shares issued to Dr. Arif Karim, the former owner of The Control Center, Inc. Dr. Karim had entered into an employment agreement with Summit Healthtech, Inc. prior to the acquisition by the Company. On October 30, 2019, the Company reached a settlement with Dr. Karim, whereby the Company and Dr. Karim released all claims against each other, including any claims under the Executive Employment Agreement between Vitality Healthtech, Inc. and Dr. Karim dated October 12, 2018, and the Share Purchase Agreement by and among The Control Center, Inc., Dr. Karim and Vitality Healthtech, Inc. also dated October 12, 2018. In exchange for the releases, the Company paid Dr. Karim $120,000, which is included in the costs to close the Company’s clinical and test kit operations, and the 1,450,000 shares of the Company’s common stock issued to Dr. Karim were cancelled with no adjustment to the purchase price recorded. The following table presents the summarized components of loss from discontinued operations for the Company’s clinical and test kit operations: Years Ended March 31, 2020 2019 Revenue $ 44,698 $ 258,288 Cost of sales 143,232 454,767 Research and development 4,361 42,792 General and administrative 630,231 882,806 Impairment of goodwill and intangible assets - 7,550,000 Loss from discontinued operations $ (733,126 ) $ (8,672,077 ) The assets and liabilities of discontinued operations are stated separately as of March 31, 2020 and 2019 in the consolidated balance sheets and are comprised of the following items: March 31, 2020 2019 Assets Accounts receivable, net $ — $ 19,360 Prepaid expenses and other current assets — 47,247 Total current assets, discontinued operations $ — $ 66,607 Liabilities Accounts payable, accrued expenses and other liabilities $ — $ 75,706

Operating Lease

Operating Lease	12 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Operating Lease	3. OPERATING LEASE At March 31, 2020, the Company has an operating lease agreement for its office space. The Company accounts for the lease and non-lease components of its office lease as a single lease component. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Under ASC 842, an operating lease right-of-use (“ROU”) asset and liability is recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The adoption of ASC 842 did not have a significant impact on our liquidity. The components of lease expense and supplemental cash flow information related to leases for the period are as follows: Year Ended March 31, 2020 Lease Cost Operating lease cost (included in general and administrative expenses in the accompanying statement of operations) $ 137,600 Other Information Cash paid for amounts included in the measurement of lease liabilities for the year ended March 31, 2020 $ 136,095 Weighted average remaining lease term – operating leases (in years) 0.9 Average discount rate – operating leases 4.0 % The supplemental balance sheet information related to leases for the period is as follows: At March 31, 2020 Operating Leases Long-term right-of-use asset $ 123,606 Short-term operating lease liability $ 125,679 Long-term operating lease liability - Total operating lease liabilities $ 125,679 Maturities of the Company’s lease liabilities are as follows: Year Ending March 31 Operating Lease 2021 $ 128,205 Total lease payments 128,205 Less: Imputed interest/present value discount (2,526 ) Present value of lease liabilities $ 125,679 Lease expenses were $153,599 and $129,248 during the years ended March 31, 2020 and March 31, 2019, respectively.

Advance

Advance	12 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Advance	4. ADVANCE In July 2018, we received a payment from a third party in the amount of $296,653. To date, the Company has not confirmed the nature of this payment. We have recorded this payment as an advance and, at March 31, 2020 and 2019, it is included in current liabilities on the accompanying financial statements.

Derivative Liability

Derivative Liability	12 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	5. DERIVATIVE LIABILITY In May 2015, the Company issued certain warrants which included a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder. In addition, the warrants contained an anti-dilution provision that allows for the automatic reset of the exercise price of the warrants upon future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants. As such the Company determined that the warrant fundamental transaction clause and exercise price created a derivative. In accordance with the FASB authoritative guidance, the fair value of the warrants was recognized as a derivative instrument and is re-measured at the end of each reporting period with the change in value reported in the statement of operations. At March 31, 2018, the balance of the derivative liabilities was $153,042. During the year ended March 31, 2019, the Company recorded a decrease in derivative liability of $117,332. At March 31, 2019, the balance of the derivative liabilities was $35,710. During the year ended March 31, 2020, the Company recorded a decrease in derivative liability of $35,710, and at March 31, 2020, the balance of derivative liabilities was zero. At March 31, 2020 and March 31, 2019, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions: March 31, 2020 March 31, 2019 Conversion feature: Risk-free interest rate 0.05 % 2.63 % Expected volatility 248 % 177 % Expected life (in years) 0.1 years 1.1 years Expected dividend yield - - Fair Value: Warrant liability $ - $ 35,710 The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	6. STOCKHOLDERS’ EQUITY Sale of common stock and warrants for cash in fiscal 2019 During the year ended March 31, 2019, the Company entered into securities purchase agreements pursuant to which the Company sold a total of 6,000,000 units of common stock and warrants at a purchase price of $1.50 per unit, resulting in net proceeds to the Company of $8,850,000 after deducting fees and expenses of the offering. Each unit consisted of one share of common stock and a warrant to purchase between one-half of one share and one share of common stock. Accordingly, 6,000,000 shares of common stock and warrants to purchase 5,833,333 shares of common stock were issued. 166,667 of the warrants had an exercise price of $2.00 per share, and 5,666,666 of the warrants had an exercise price of $3.00 per share. The warrants vested immediately and expire in five years. On January 18, 2019, the Company amended the securities purchase agreements. Pursuant to the amendments, the warrants to purchase the 5,833,333 shares of the Company’s common stock were cancelled, and the investors were issued an additional 16,750,000 shares of the Company’s common stock for no additional consideration. The fair value of the 16,750,000 shares issued was $9,715,000 and the fair value of the 5,833,333 warrants cancelled was $2,700,000. The difference of $7,015,000 was recorded as a deemed dividend to the investors. Common stock issued for acquisition in fiscal 2019 On October 19, 2018, the Company issued 6,000,000 shares of the Company’s common stock in exchange for all of the outstanding common stock of Summit Healthtech (see Note 2). In February 2019, June 2019, and October 2019, the Company cancelled a total of 2,450,000 shares of the Company’s common stock that had been issued as part of the share exchange agreement (see Note 2).

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	7. STOCK BASED COMPENSATION Stock options issued during fiscal 2020 During the year ended March 31, 2020, the Company granted to directors and employees options to purchase an aggregate of 3,250,000 shares of the Company’s common stock with exercise prices of $0.30 to $0.35 per share, that expire ten years from the date of grant, and all have vesting periods of 24 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes-Merton option pricing model based on the following assumptions: (i) volatility rate of 176.50%, (ii) discount rate of 1.73%, (iii) zero expected dividend yield, and (iv) expected life of 6 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $1,026,000. Stock options issued during fiscal 2019 During the year ended March 31, 2019, the Company granted an aggregate of 200,000 options to purchase shares of the Company’s common stock with exercise prices ranging from $1.62 to $1.95 per share to two employees that expire ten years from the date of grant. The options issued have a vesting period of three years. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate between 117.91% and 119.34%, (ii) discount rate between 2.79% and 2.98%, (iii) zero expected dividend yield, and (iv) expected life of 6 years, which is the average of the term of the options and their vesting periods. The total fair value of these option grants at their grant dates was approximately $324,000. During the years ended March 31, 2020 and 2019, total stock-based compensation expense related to vested stock options was $626,668 and $765,648, respectively. At March 31, 2020, the remaining unamortized cost of the outstanding stock-based awards was approximately $587,000 and will be amortized on a straight-line basis over a weighted average remaining vesting period of 2 years. A summary of the Company’s stock option activity during the fiscal years ended March 31, 2019 and 2020 is as follows: Shares Weighted Average Exercise Price Balance at March 31, 2018 3,316,710 $ 1.40 Granted 200,000 1.87 Exercised - Expired (60,000 ) 2.00 Cancelled - - Balance outstanding at March 31, 2019 3,456,710 $ 1.40 Granted 3,250,000 0.34 Exercised - Expired - - Cancelled (160,000 ) 1.92 Balance outstanding at March 31, 2020 6,546,710 $ 0.89 Balance exercisable at March 31, 2020 3,271,711 $ 1.26 At March 31, 2020, the 6,546,710 outstanding stock options had no intrinsic value. A summary of the Company’s stock options outstanding and exercisable as of March 31, 2020 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Grant- Options Outstanding, March 31, 2020 750,000 $ 0.30 $ 0.30 2,500,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 517,500 $ 1.50-1.95 $ 1.50-1.950 687,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 6,546,710 Options Exercisable, March 31, 2020 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 492,501 $ 1.50-1.95 $ 1.50-1.95 687,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 3,271,711 Common stock issued to employees with vesting terms At April 1, 2018, the Company had issued an aggregate of 1,636,170 shares of its common stock to an officer and a director of the Company, with aggregate fair value of $1,080,000, and recognized as stock compensation expense ratably over the vesting terms which ranged from 14 months to 2.5 years. During the year ended March 31, 2019, total stock-based compensation recognized on the shares granted was $356,270, and at March 31, 2019, all of the shares had vested. During the year ended March 31, 2020, there was no stock-based compensation recognized on the shares. The following table summarizes restricted common stock activity: Number of shares Fair value of shares Non-vested shares, March 31, 2018 1,636,170 $ 1,080,000 Granted - - Vested (1,636,170 ) (1,080,000 ) Forfeited - - Non-vested shares, March 31, 2019 - $ - Granted - - Vested - - Forfeited - - Non-vested shares, March 31, 2020 - $ - Common stock issued for services During the year ended March 31, 2019, the Company issued a total of 265,000 shares of common stock to consultants as payment for services and recorded expenses of $348,451 based on the fair value of the Company’s common stock at the issuance date. During the year ended March 31, 2020, the Company did not issue any common stock as payment for services.

Warrants

Warrants	12 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants	8. WARRANTS A summary of warrants to purchase common stock issued during the fiscal years ended March 31, 2019 and 2020 is as follows: Shares Weighted Average Exercise Price Balance outstanding at March 31, 2018 1,164,422 $ 2.19 Granted 5,833,333 2.97 Exercised - - Expired/Cancelled (5,862,752 ) 2.98 Balance outstanding at March 31, 2019 1,135,003 $ 2.19 Granted - - Exercised - - Expired/Cancelled - - Balance outstanding and exercisable at March 31, 2020 1,135,003 $ 2.19 At March 31, 2020, the 1,135,003 outstanding stock warrants had no intrinsic value. Stock warrants issued during fiscal 2020 The Company did not issue any warrants during the year ended March 31, 2020. Stock warrants issued during fiscal 2019 In August 2018 and October 2018, we issued warrants to purchase an aggregate of 5,833,333 shares of the Company’s common stock with exercise prices ranging from $2.00 to $3.00 per share (see Note 6). These warrants were cancelled in January 2019.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	9. INCOME TAXES The Company had no income tax expense for the years ended March 31, 2020 or 2019 due to its history of operating losses. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate: Year Ended March 31, 2020 2019 Federal Statutory tax rate (21 )% (21 )% State tax, net of federal benefit (7 )% (7 )% (28 )% (28 )% Valuation allowance 28 % 28 % Effective tax rate - % - % Deferred tax assets and liabilities consist of the following: March 31, 2020 2019 Net deferred tax assets: Net operating loss carryforwards $ 5,364,000 $ 4,524,000 Stock-based compensation 3,071,000 2,895,000 Research credits 64,000 40,000 Operating lease liability 35,000 - Gross deferred tax assets 8,534,000 7,459,000 Less: valuation allowance (7,658,000 ) (6,628,000 ) Total deferred tax assets 876,000 831,000 Deferred tax liabilities: Derivative income 841,000 831,000 Operating lease right-of-use asset 35,000 - Total deferred tax liabilities 876,000 831,000 Net deferred income tax assets (liabilities) $ - $ - The provisions of ASC Topic 740, Accounting for Income Taxes At March 31, 2020 and 2019, the Company had available Federal and state net operating loss carryforwards (“NOLs”) to reduce future taxable income. For Federal purposes, the amounts available were approximately $19.7 million and $16.7 million, respectively. For state purposes, approximately $17.4 million and $14.4 million was available at March 31, 2020 and 2019, respectively. The Federal carryforwards expire on various dates through 2040 and the state carryforwards expire through 2037. Due to restrictions imposed by Internal Revenue Code Section 382 regarding substantial changes in ownership of companies with loss carryforwards, the utilization of the Company’s NOLs may be limited as a result of changes in stock ownership. NOLs incurred subsequent to the latest change in control are not subject to the limitation. The Company’s operations are based in California and it is subject to Federal and California state income tax. Tax years after 2015 are open to examination by United States and state tax authorities. The Company adopted the provisions of ASC 740, which requires companies to determine whether it is “more likely than not” that a tax position will be sustained upon examination by the appropriate taxing authorities before any tax benefit can be recorded in the financial statements. ASC 740 also provides guidance on the recognition, measurement, classification and interest and penalties related to uncertain tax positions. As of March 31, 2020 and 2019, no liability for unrecognized tax benefits was required to be recorded or disclosed.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	10. RELATED PARTY TRANSACTIONS During the year ended March 31, 2019, the Company paid rent of $31,200 to One World Ranches LLC, which is jointly-owned by Dr. Avtar Dhillon, the former Chairman of the Board of Directors of the Company, and his wife. During the year ended March 31, 2020, rental payments to One World Ranches LLC totaled $2,600. During the year ended March 31, 2015, the Company purchased certain assets of Percipio Biosciences, Inc. (“Percipio”) for $50,000. The Company’s former Chief Executive Officer owned 20% of Percipio. At March 31, 2019, $10,500 of the purchase price remained unpaid and was included in current liabilities of discontinued operations on the accompanying balance sheet. This balance was reduced to zero when the operations of Percipio were discontinued during the year ended March 31, 2020. Included in the deemed dividend of $7,015,000 (see Note 6) recorded on January 18, 2019, was $1,022,975 related to 2,442,708 shares of the Company’s common stock that we issued to two directors of the Company.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. COMMITMENTS AND CONTINGENCIES SEC Investigation On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. On May 12, 2020, our outside legal counsel received a letter from the staff of the SEC’s Enforcement Division stating that it has concluded the investigation as to the Company, and that it did not intend to recommend an enforcement action by the SEC against the Company. We may be required to reimburse certain former officers and directors for legal fees related to this matter, but at March 31, 2020, management determined that the liability for those fees is not probable and we could not reasonably estimate those fees.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	12. SUBSEQUENT EVENTS In May 2020, we received a loan under the Small Business Administration’s Payroll Protection Program of approximately $97,000. The loan bears interest at 1% per annum and matures in two years. In accordance with the terms of the Payroll Protection Program, a portion of this loan may be forgiven if the loan proceeds are used for payroll, rent and utility costs, as defined.

Business Operations and Summa_2

Business Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Liquidity We are currently engaged in the development of cannabinoid prodrug pharmaceuticals, we do not have any commercial products, and have not yet generated significant revenues from sales of products or services. As reflected in the accompanying financial statements, during the year ended March 31, 2020, the Company incurred a net loss of $4,365,355 and used $3,590,516 of cash in our operating activities. As of March 31, 2020, we had $2,392,225 of cash on hand, stockholders’ equity of $1,282,389 and working capital of $1,123,031. Our total expenditures for the fiscal year ending March 31, 2021, are expected to be approximately $1,600,000, which is comprised of research and development and general operating expenses. We believe that we have sufficient capital to fund our anticipated operating expenses for at least one year from the date that the financial statements are issued. While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations, we may require additional financing to fund our planned future operations. Further, these estimates could differ if we encounter unanticipated difficulties, or if our estimates of the amount of cash necessary to operate our business prove to be wrong, and we use our available financial resources faster than we currently expect. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company.
COVID-19 Outbreak	COVID-19 Outbreak The global outbreak of COVID-19 has led to significant disruptions in the global economy, including the curtailment of activities by businesses and consumers in much of the world as governments and others seek to limit the spread of the disease. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration and severity of the outbreak, the length of restrictions and business closures imposed by domestic and foreign governments, the impact on capital and financial markets, all of which are highly uncertain and cannot be predicted. While it is not possible at this time to estimate the full impact that COVID-19 will have on our business, restrictions resulting from COVID-19 on general economic conditions could, among other things, impair our ability to raise capital when needed. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Vitality Healthtech, Inc. and have been prepared in accordance with accounting principles generally accepted in the United States of America. Intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year end is March 31
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, estimates inherent in recording purchase price allocation, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances.
Business Combinations	Business Combinations The Company accounts for its business combinations using the purchase method of accounting where the cost is allocated to the underlying net tangible and intangible assets acquired, based on their respective fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Identifiable assets acquired, liabilities assumed and any noncontrolling interest in the acquiree are recognized and measured as of the acquisition date at fair value. Additionally, contingent consideration, if any, is recorded at fair value on the acquisition date and classified as a liability. Goodwill is recognized to the extent by which the aggregate of the acquisition-date fair value of the consideration transferred and any noncontrolling interest in the acquiree exceeds the recognized basis of the identifiable assets acquired, net of assumed liabilities. Determining the fair value of assets acquired, liabilities assumed and noncontrolling interests requires management’s judgment and often involves the use of significant estimates and assumptions.
Goodwill and Intangible Assets	Goodwill and Intangible Assets The Company follows Accounting Standards Codification (ASC) 350 in accounting for intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Under the guidance of ASC 350, goodwill is not amortized, rather it is tested for impairment annually, and will be tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss generally would be recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit and would be measured as the excess carrying value of goodwill over the derived fair value of goodwill. For the year ended March 31, 2019, the Company recorded impairment of goodwill and intangible assets of $7,550,000 (See Note 2). For the year ended March 31, 2020, the Company did not record any impairment of goodwill and intangible assets.
Financial Assets and Liabilities Measured at Fair Value	Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. As of March 31, 2020 and March 31, 2019, the Company’s balance sheet includes Level 2 liabilities comprised of the fair value of embedded derivative liabilities of $0 and $35,710, respectively (see Note 5). The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative during the years ended March 31, 2020 and 2019: Year ended March 31, 2020 Year ended March 31, 2019 Fair value at beginning of period $ 35,710 $ 153,042 Net change in the fair value of derivative liabilities (35,710 ) (117,332 ) Fair value at end of period $ - $ 35,710
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the March 31, 2020, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
Leases	Leases Prior to April 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases Leases
Stock-Based Compensation	Stock-Based Compensation The Company issues stock options and warrants, shares of common stock, and shares of restricted common stock as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with ASC 718, Compensation – Stock Compensation In prior periods through March 31, 2019, the Company accounted for share-based payments to non-employees in accordance with ASC 505-50, Equity - Based Payments to Non-Employees On April 1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-07 which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions is measured by estimating the fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions. The adoption of the standard did not have a material impact on our financial statements.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: March 31, 2020 2019 Options 6,546,710 3,456,710 Warrants 1,135,003 1,135,003 Total 7,681,713 4,591,713
Patents and Patent Application Costs	Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Accordingly, patent costs are expensed as incurred.
Research and Development	Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.
Segments	Segments The Company operates in one segment for the development of pharmaceuticals products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.
Reclassifications	Reclassifications Certain amounts related to revenue and expenses of discontinued operations for the year ended March 31, 2019, and assets and liabilities attributable to discontinued operations at March 31, 2019, have been reclassified to conform to classifications used in the current year as a result of the discontinued operations presentation. The reclassifications had no effect on previously reported results of consolidated operations or retained earnings (see Note 2).
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Business Operations and Summa_3

Business Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Fair Value of Derivative Liabilities	The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative during the years ended March 31, 2020 and 2019: Year ended March 31, 2020 Year ended March 31, 2019 Fair value at beginning of period $ 35,710 $ 153,042 Net change in the fair value of derivative liabilities (35,710 ) (117,332 ) Fair value at end of period $ - $ 35,710
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: March 31, 2020 2019 Options 6,546,710 3,456,710 Warrants 1,135,003 1,135,003 Total 7,681,713 4,591,713

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations for Summit Healthcare	The following table presents the summarized components of loss from discontinued operations for the Company’s clinical and test kit operations: Years Ended March 31, 2020 2019 Revenue $ 44,698 $ 258,288 Cost of sales 143,232 454,767 Research and development 4,361 42,792 General and administrative 630,231 882,806 Impairment of goodwill and intangible assets - 7,550,000 Loss from discontinued operations $ (733,126 ) $ (8,672,077 ) The assets and liabilities of discontinued operations are stated separately as of March 31, 2020 and 2019 in the consolidated balance sheets and are comprised of the following items: March 31, 2020 2019 Assets Accounts receivable, net $ — $ 19,360 Prepaid expenses and other current assets — 47,247 Total current assets, discontinued operations $ — $ 66,607 Liabilities Accounts payable, accrued expenses and other liabilities $ — $ 75,706

Operating Lease (Tables)

Operating Lease (Tables)	12 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Lease Expenses	The components of lease expense and supplemental cash flow information related to leases for the period are as follows: Year Ended March 31, 2020 Lease Cost Operating lease cost (included in general and administrative expenses in the accompanying statement of operations) $ 137,600 Other Information Cash paid for amounts included in the measurement of lease liabilities for the year ended March 31, 2020 $ 136,095 Weighted average remaining lease term – operating leases (in years) 0.9 Average discount rate – operating leases 4.0 %
Schedule of Supplement Related to Lease	The supplemental balance sheet information related to leases for the period is as follows: At March 31, 2020 Operating Leases Long-term right-of-use asset $ 123,606 Short-term operating lease liability $ 125,679 Long-term operating lease liability - Total operating lease liabilities $ 125,679
Schedule of Maturities of Lease Liabilities	Maturities of the Company’s lease liabilities are as follows: Year Ending March 31 Operating Lease 2021 $ 128,205 Total lease payments 128,205 Less: Imputed interest/present value discount (2,526 ) Present value of lease liabilities $ 125,679

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Valuation Assumptions for Derivative Liabilities	At March 31, 2020 and March 31, 2019, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions: March 31, 2020 March 31, 2019 Conversion feature: Risk-free interest rate 0.05 % 2.63 % Expected volatility 248 % 177 % Expected life (in years) 0.1 years 1.1 years Expected dividend yield - - Fair Value: Warrant liability $ - $ 35,710

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity during the fiscal years ended March 31, 2019 and 2020 is as follows: Shares Weighted Average Exercise Price Balance at March 31, 2018 3,316,710 $ 1.40 Granted 200,000 1.87 Exercised - Expired (60,000 ) 2.00 Cancelled - - Balance outstanding at March 31, 2019 3,456,710 $ 1.40 Granted 3,250,000 0.34 Exercised - Expired - - Cancelled (160,000 ) 1.92 Balance outstanding at March 31, 2020 6,546,710 $ 0.89 Balance exercisable at March 31, 2020 3,271,711 $ 1.26
Schedule of Stock Options Outstanding and Exercisable	A summary of the Company’s stock options outstanding and exercisable as of March 31, 2020 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Grant- Options Outstanding, March 31, 2020 750,000 $ 0.30 $ 0.30 2,500,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 517,500 $ 1.50-1.95 $ 1.50-1.950 687,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 6,546,710 Options Exercisable, March 31, 2020 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 492,501 $ 1.50-1.95 $ 1.50-1.95 687,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 3,271,711
Schedule of Nonvested Restricted Stock Unit Activity	The following table summarizes restricted common stock activity: Number of shares Fair value of shares Non-vested shares, March 31, 2018 1,636,170 $ 1,080,000 Granted - - Vested (1,636,170 ) (1,080,000 ) Forfeited - - Non-vested shares, March 31, 2019 - $ - Granted - - Vested - - Forfeited - - Non-vested shares, March 31, 2020 - $ -

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Activity	A summary of warrants to purchase common stock issued during the fiscal years ended March 31, 2019 and 2020 is as follows: Shares Weighted Average Exercise Price Balance outstanding at March 31, 2018 1,164,422 $ 2.19 Granted 5,833,333 2.97 Exercised - - Expired/Cancelled (5,862,752 ) 2.98 Balance outstanding at March 31, 2019 1,135,003 $ 2.19 Granted - - Exercised - - Expired/Cancelled - - Balance outstanding and exercisable at March 31, 2020 1,135,003 $ 2.19

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate: Year Ended March 31, 2020 2019 Federal Statutory tax rate (21 )% (21 )% State tax, net of federal benefit (7 )% (7 )% (28 )% (28 )% Valuation allowance 28 % 28 % Effective tax rate - % - %
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities consist of the following: March 31, 2020 2019 Net deferred tax assets: Net operating loss carryforwards $ 5,364,000 $ 4,524,000 Stock-based compensation 3,071,000 2,895,000 Research credits 64,000 40,000 Operating lease liability 35,000 - Gross deferred tax assets 8,534,000 7,459,000 Less: valuation allowance (7,658,000 ) (6,628,000 ) Total deferred tax assets 876,000 831,000 Deferred tax liabilities: Derivative income 841,000 831,000 Operating lease right-of-use asset 35,000 - Total deferred tax liabilities 876,000 831,000 Net deferred income tax assets (liabilities) $ - $ -

Business Operations and Summa_4

Business Operations and Summary of Significant Accounting Policies (Details Narrative)	Apr. 02, 2019USD ($)	Mar. 31, 2020USD ($)Integer	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Net loss		$ (4,365,355)	$ (13,121,567)
Net cash used in operating activities		(3,590,516)	(3,665,094)
Cash on hand		2,392,225
Stockholders' equity		1,282,389	5,021,076	$ 322,274
Working capital		1,123,031
Total expected expenditure for operating expenses and investment activity		1,600,000
Impairment of goodwill and intangible assets		7,550,000
Fair value of embedded derivative liabilities		0	35,710
Operating lease, right-of-use asset		123,606
Lease liabilities for operating leases		$ 125,679
Number of operating segments | Integer		1
Accounting Standards Update 2016-02 [Member]
Operating lease, right-of-use asset	$ 253,387
Lease liabilities for operating leases	253,387
Cumulative-effect adjustment to accumulated deficit	$ 0

Business Operations and Summa_5

Business Operations and Summary of Significant Accounting Policies - Schedule of Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fair value at beginning of period	$ 35,710	$ 153,042
Net change in the fair value of derivative liabilities	(35,710)	(117,332)
Fair value at end of period		$ 35,710

Business Operations and Summa_6

Business Operations and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive securities excluded from computation of earnings per share	7,681,713	4,591,713
Options [Member]
Antidilutive securities excluded from computation of earnings per share	6,546,710	3,456,710
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	1,135,003	1,135,003

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)	Oct. 12, 2018	Oct. 31, 2018	Mar. 31, 2020	Mar. 31, 2019	Jun. 29, 2020
Severance and related benefits			$ 1,009,894	$ 1,742,919
Dr. Karim [Member]
Number of shares cancelled	1,450,000
Cost of disposal paid	$ 120,000
Summit Healthtech Inc [Member] | Dr Arif Karim [Member]
Common stock, shares issued			1,450,000
Clinical and Test Kit Operations [Member]
Severance and related benefits			$ 165,000
Summit Healthtech [Member]
Common stock, shares issued		6,000,000
Common stock, shares issued, value		$ 9,000,000
Shares issued, price per share		$ 1.50
Business combination, net assets acquired		$ 180,315
Business combination, net liabilities assumed		230,315
Business combination, goodwill and intangible assets		$ 9,550,000
Business combination, goodwill and intangible assets percentage				100.00%
Business combination, impairment loss				$ 7,550,000
Summit Healthtech [Member] | Subsequent Event [Member]
Number of shares cancelled					2,450,000
Business combination, purchase price					$ 7,500,000
Business combination, purchase price adjusted					$ 7,550,000

Discontinued Operations - Sched

Discontinued Operations - Schedule of Discontinued Operations for Summit Healthcare (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Revenue	$ 44,698	$ 258,288
Cost of sales	143,232	454,767
Research and development	4,361	42,792
General and administrative	630,231	882,806
Impairment of goodwill and intangible assets		7,550,000
Loss from discontinued operations	(733,126)	(8,672,077)
Accounts receivable, net		19,360
Prepaid expenses and other current assets		47,247
Total current assets, discontinued operations		66,607
Accounts payable, accrued expenses and other liabilities		$ 75,706

Operating Lease (Details Narra

Operating Lease (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Lease expenses	$ 129,781
Operating Lease Agreement [Member]
Lease expenses	$ 153,599	$ 129,248

Operating Lease - Schedule of L

Operating Lease - Schedule of Lease Expenses (Details)	12 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Operating lease cost (included in general and administrative expenses in the accompanying statement of operations)	$ 137,600
Cash paid for amounts included in the measurement of lease liabilities for the year ended March 31, 2020	$ 136,095
Weighted average remaining lease term - operating leases (in years)	10 months 25 days
Average discount rate - operating leases	4.00%

Operating Lease - Schedule of S

Operating Lease - Schedule of Supplement Related to Lease (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating Leases: Long-term right-of-use asset	$ 123,606
Operating Leases: Short-term operating lease liability	125,679
Operating Leases: Long-term operating lease liability
Operating Leases: Total operating lease liabilities	$ 125,679

Operating Lease - Schedule of M

Operating Lease - Schedule of Maturities of Lease Liabilities (Details)	Mar. 31, 2020USD ($)
Leases [Abstract]
2021	$ 128,205
Total lease payments	128,205
Less: Imputed interest/present value discount	(2,526)
Present value of lease liabilities	$ 125,679

Advance (Details Narrative)

Advance (Details Narrative) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Jul. 31, 2018
Receivables [Abstract]
Advance	$ 296,653	$ 296,653	$ 296,653

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities		$ 35,710	$ 153,042
Decrease in derivative liability	$ 35,710	$ 117,332

Derivative Liability - Schedule

Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details)	12 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value: Warrant liability		$ 35,710	$ 153,042
Risk-free Interest Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, measurement input	0.05	2.63
Expected Volatility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, measurement input	248	177
Expected Life [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, term	1 month 6 days	1 year 1 month 6 days
Expected Dividend Yield [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, measurement input	0	0

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Jan. 18, 2019	Oct. 19, 2018	Oct. 31, 2019	Jun. 30, 2019	Feb. 28, 2019	Mar. 31, 2019
Number of shares issued for additional consideration, value						$ 8,850,000
Common stock issued for acquisition, shares		6,000,000
Number of shares cancelled						1,000,000
Warrant One [Member]
Warrants to purchase common stock						166,667
Warrants exercise price						$ 2
Warrant Two [Member]
Warrants to purchase common stock						5,666,666
Warrants exercise price						$ 3
Securities Purchase Agreement [Member]
Stock issued during period, shares, new issues						6,000,000
Shares issued price per shares						$ 1.50
Proceeds from sale of common stock and warrants, net						$ 8,850,000
Warrants to purchase common stock						5,833,333
Expiraion of warrants						5 years
Warrants to purchase common stock shares, cancelled	5,833,333
Warrants to purchase common stock shares, cancelled value	$ 2,700,000
Securities Purchase Agreement [Member] | Investor [Member]
Number of shares issued for additional consideration	16,750,000
Number of shares issued for additional consideration, value	$ 9,715,000
Deemed dividend	$ 7,015,000
Share Exchange Agreement [Member]
Number of shares cancelled			2,450,000	2,450,000	2,450,000

Stock Based Compensation (Detai

Stock Based Compensation (Details Narrative) - USD ($)	Apr. 02, 2018	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase an aggregate shares of common stock		3,250,000	200,000
Common stock with exercise prices		$ 0.34	$ 1.87
Stock option expiration term		10 years	10 years
Stock option granted, vesting periods		24 months	3 years
Volatility rate		176.50%
Discount rate		1.73%
Dividend yield		0.00%	0.00%
Expected life		6 years	6 years
Fair value of the option grants		$ 1,026,000	$ 324,000
Stock-based compensation expense		626,668	$ 765,648
Unamortized cost of outstanding stock-based awards		$ 587,000
Weighted average remaining vesting period		2 years
Outstanding stock options		6,546,710	3,456,710	3,316,710
Stock warrants, intrinsic value
Stock based compensation expenses on shares granted			$ 356,270
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues	1,636,170
Fair value of common stock	$ 1,080,000
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued for services			265,000
Payment for stock issuance cost			$ 348,451
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock with exercise prices		$ 0.30	$ 1.62
Volatility rate			117.91%
Discount rate			2.79%
Minimum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, vesting periods	14 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock with exercise prices		$ 0.35	$ 1.95
Volatility rate			119.34%
Discount rate			2.98%
Maximum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, vesting periods	2 years 6 months

Stock Based Compensation - Summ

Stock Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance Outstanding	3,456,710	3,316,710
Shares, Granted	3,250,000	200,000
Shares, Exercised
Shares, Expired		(60,000)
Shares, Cancelled	(160,000)
Shares Outstanding, Ending Balance	6,546,710	3,456,710
Shares, Balance Exercisable	3,271,711
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 1.40	$ 1.40
Weighted Average Exercise Price, Granted	0.34	1.87
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired		2
Weighted Average Exercise Price, Cancelled	1.92
Weighted Average Exercise Price, Outstanding Ending Balance	0.89	$ 1.40
Weighted Average Exercise Price, Balance Exercisable	$ 1.26

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock Options Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	6,546,710	3,456,710	3,316,710
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.34	$ 1.87
Number of Options, Options Exercisable	3,271,711
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.30	1.62
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.35	$ 1.95
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	750,000
Weighted Average Exercise Price, Options Outstanding	$ 0.30
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.30
Number of Options, Options Exercisable	1,664,542
Weighted Average Exercise Price, Options Exercisable	$ 0.50
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.50
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	2,500,000
Weighted Average Exercise Price, Options Outstanding	$ 0.35
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.35
Number of Options, Options Exercisable	128,000
Weighted Average Exercise Price, Options Exercisable	$ 0.96
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.96
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	1,664,542
Weighted Average Exercise Price, Options Outstanding	$ 0.50
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.50
Number of Options, Options Exercisable	130,000
Weighted Average Exercise Price, Options Exercisable	$ 1
Weighted Average Grant-date Stock Price, Options Exercisable	$ 10
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	128,000
Weighted Average Exercise Price, Options Outstanding	$ 0.96
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.96
Number of Options, Options Exercisable	492,501
Stock Options Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	$ 1.50
Weighted Average Grant-date Stock Price, Options Exercisable	1.50
Stock Options Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	1.95
Weighted Average Grant-date Stock Price, Options Exercisable	$ 1.95
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	130,000
Weighted Average Exercise Price, Options Outstanding	$ 1
Weighted Average Grant-date Stock Price, Options Outstanding	$ 10
Number of Options, Options Exercisable	687,500
Stock Options Five [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	$ 2
Weighted Average Grant-date Stock Price, Options Exercisable	2
Stock Options Five [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	2.79
Weighted Average Grant-date Stock Price, Options Exercisable	$ 2.79
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	517,500
Number of Options, Options Exercisable	123,334
Stock Options Six [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 1.50
Weighted Average Grant-date Stock Price, Options Outstanding	1.50
Weighted Average Exercise Price, Options Exercisable	3.10
Weighted Average Grant-date Stock Price, Options Exercisable	3.10
Stock Options Six [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	1.95
Weighted Average Grant-date Stock Price, Options Outstanding	1.950
Weighted Average Exercise Price, Options Exercisable	3.80
Weighted Average Grant-date Stock Price, Options Exercisable	$ 3.80
Stock Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	687,500
Number of Options, Options Exercisable	45,834
Stock Options Seven [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 2
Weighted Average Grant-date Stock Price, Options Outstanding	2
Weighted Average Exercise Price, Options Exercisable	4
Weighted Average Grant-date Stock Price, Options Exercisable	4
Stock Options Seven [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	2.79
Weighted Average Grant-date Stock Price, Options Outstanding	2.79
Weighted Average Exercise Price, Options Exercisable	4.70
Weighted Average Grant-date Stock Price, Options Exercisable	$ 4.70
Stock Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	123,334
Stock Options Eight [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 3.10
Weighted Average Grant-date Stock Price, Options Outstanding	3.10
Stock Options Eight [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	3.80
Weighted Average Grant-date Stock Price, Options Outstanding	$ 3.80
Stock Options Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Options Outstanding	45,834
Stock Options Nine [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 4
Weighted Average Grant-date Stock Price, Options Outstanding	4
Stock Options Nine [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	4.70
Weighted Average Grant-date Stock Price, Options Outstanding	$ 4.70

Stock Based Compensation - Sc_2

Stock Based Compensation - Schedule of Nonvested Restricted Stock Unit Activity (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Non-vested shares, Number of shares, Beginning balance		1,636,170
Non-vested shares, Number of shares, Granted
Non-vested shares, Number of shares, Vested		(1,636,170)
Non-vested shares, Number of shares, Forfeited
Non-vested shares, Number of shares, Ending balance
Non-vested shares, Fair value of shares, Beginning balance		$ 1,080,000
Non-vested shares, Fair value of shares, Granted
Non-vested shares, Fair value of shares, Vested		(1,080,000)
Non-vested shares, Fair value of shares, Forfeited
Non-vested shares, Fair value of shares, Ending balance

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Oct. 31, 2018	Aug. 31, 2018
Stock warrants, intrinsic value
Warrants [Member]
Outstanding warrants	1,135,003
Stock warrants, intrinsic value
Stock warrants, issued		5,833,333
Warrants to purchase			5,833,333	5,833,333
Warrants [Member] | Minimum [Member]
Warrants exercise price			$ 2	$ 2
Warrants [Member] | Maximum [Member]
Warrants exercise price			$ 3	$ 3

Warrants - Summary of Warrants

Warrants - Summary of Warrants Activity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Number of Shares, Warrants Outstanding, Beginning Balance	1,135,003	1,164,422
Number of Shares, Warrants Granted		5,833,333
Number of Shares, Warrants Exercised
Number of Shares, Warrants Expired/Cancelled		(5,862,752)
Number of Shares, Warrants Outstanding and Exercisable Ending Balance	1,135,003	1,135,003
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance	$ 2.19	$ 2.19
Weighted Average Exercise Price, Warrants Outstanding, Granted		2.97
Weighted Average Exercise Price, Warrants Outstanding, Exercised
Weighted Average Exercise Price, Warrants Outstanding, Expired/Cancelled		2.98
Weighted Average Exercise Price, Warrants Outstanding, Outstanding and Exercisable, Ending Balance	$ 2.19	$ 2.19

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Increased in valuation allowances	$ 1,000,000	$ 500,000
Federal net operating loss carryforwards	19,700,000	16,700,000
State net operating loss carryforwards	$ 17,400,000	14,400,000
Income tax description	The Federal carryforwards expire on various dates through 2040 and the state carryforwards expire through 2037.
Liability for unrecognized tax benefits

Income Taxes - Schedule of Eff

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Federal Statutory tax rate	(21.00%)	(21.00%)
State tax, net of federal benefit	(7.00%)	(7.00%)
Effective tax rate, before valuation allowance	(28.00%)	(28.00%)
Valuation allowance	28.00%	28.00%
Effective tax rate	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 5,364,000	$ 4,524,000
Stock-based compensation	3,071,000	2,895,000
Research credits	64,000	40,000
Operating lease liability	35,000
Gross deferred tax assets	8,534,000	7,459,000
Less: valuation allowance	(7,658,000)	(6,628,000)
Total deferred tax assets	876,000	831,000
Derivative income	841,000	831,000
Operating lease right-of-use asset	35,000
Total deferred tax liabilities	876,000	831,000
Net deferred income tax assets (liabilities)

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 18, 2019	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2015
Deemed dividend on issuance of shares	$ 7,015,000
One World Ranches LLC [Member]
Rental payments		$ 2,600	31,200
Percipio Biosciences, Inc [Member]
Payments to acquire assets				$ 50,000
Purchase price, unpaid value		$ 0	$ 10,500
Percipio Biosciences, Inc [Member] | Chief Executive Officer [Member]
Ownership percentage				20.00%
Two Directors [Member]
Fair value of common stock	$ 1,022,975
Number of common shares issued during period	2,442,708

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Aug. 19, 2016shares
Common Stock One [Member]
Common stock issuable upon exercise of certain warrants	2,650,000
Common Stock Two [Member]
Common stock issuable upon exercise of certain warrants	7,950,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Payroll Protection Program [Member]	1 Months Ended
	May 31, 2020USD ($)
Loans receivable	$ 97,000
Loan bears interest	1.00%
Loan maturity term	2 years